Concepedia
Statistics
Publications
4
Citations
51
H-Index
Active since
2019
Affiliations
Fosun Pharma (China)(Current)
Shanghai Institute of Materia Medica
Chinese Academy of Sciences
University of Chinese Academy of Sciences
Xingdong Zhao is an author at Fosun Pharma (China) specializing in pharmacology, molecular oncology, and oncology.
Publications per year
2019–2021
SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors
Zongjun Xia, Yinchun Ji, Deqiao Sun et al. · Acta Pharmacologica Sinica · 2020 · 16 citations · Full text
Medicine, Medicinal Chemistry, Pharmacology +10
Abstract 1951: FCN-159: A novel, potent and selective oral inhibitor of MEK1/2 for the treatment of solid tumors
Shu Yu Lin, Xingdong Zhao, Zuwen Zhou et al. · Cancer Research · 2020 · 14 citations
Medicine, Oncology, Pharmacology +16
SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma
Xi Zhang, Yuting Duan, Yi Wang et al. · Acta Pharmacologica Sinica · 2021 · 11 citations · Full text
Medicine, Oncology, Pharmacology +8
Abstract 4425: FCN-437: A novel, potent and selective oral inhibitor of CDK4/6 for the treatment of solid tumors
Shu Lin, Xingdong Zhao, Tong‐Shuang Li et al. · Cancer Research · 2019 · 10 citations
Medicine, Oncology, Pharmacology +17
1–4 of 4